Is the superbug fungus really so scary? A systematic review and meta-analysis of global epidemiology and mortality of Candida auris

Jingjing Chen 1,2,3†, Sufei Tian 1,2,3†, Xiaoxu Han 1,2,3†, Yunzhuo Chu 1,2,3, Qihui Wang 1,2,3, Baosen Zhou 4 and Hong Shang 1,2,3*†

Abstract

Background: Candida auris is a new pathogen called “superbug fungus” which caused panic worldwide. There are no large-scale epidemiology studies by now, therefore a systematic review and meta-analysis was undertaken to determine the epidemic situation, drug resistance patterns and mortality of C. auris.

Methods: We systematically searched studies on the clinical report of Candida auris in Pubmed, Embase and Cochrane databases until October 6, 2019. A standardized form was used for data collection, and then statistics was performed with STATA11.0.

Results: It showed that more than 4733 cases of C. auris were reported in over 33 countries, with more cases in South Africa, United States of America, India, Spain, United Kingdom, South Korea, Colombia and Pakistan. C. auris exhibited a decrease in case count after 2016. Clade I and III were the most prevalent clades with more cases reported and wider geographical distribution. Blood stream infection was observed in 32% of the cases, which varied depending on the clades. Resistance to fluconazole, amphotericin B, caspofungin, micafungin and anidulafungin in C. auris were 91, 12, 12.1, 0.8 and 1.1%. The overall mortality of C. auris infection was 39%. Furthermore, subgroup analyses showed that mortality was higher in bloodstream infections (45%), and lower in Europe (20%).

Conclusions: Over 4000 cases of C. auris were reported in at least 33 countries, which showed high resistance to fluconazole, moderate resistance to amphotericin B and caspofungin, high sensitivity to micafungin and anidulafungin. The crude mortality for BSI of C. auris was 45% which was similar to some drug-resistant bacteria previously reported. In conclusion, C. auris displayed similar characteristics to some drug resistance organisms. This study depicts several issues of C. auris that are most concerned, and is of great significance for the clinical management.

Keywords: Candida auris, Case count, Drug resistance, Mortality, Bloodstream infection, Clade

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

*Candida auris* is a recently emerging nosocomial pathogen which was initially described in Japan in 2009 and then reported in over 30 countries worldwide afterwards [1, 2]. *C. auris* is usually resistant to several drugs, such as fluconazole, voriconazole, amphotericin B. However, resistance rate varies between studies. According to the genome sequences, *C. auris* isolates were divided into four clades that were separated by tens of thousands of SNPs: Clade I (South Asian), Clade II (East Asian), Clade III (South African), Clade IV (South American) [3]. Besides, a potential Clade V was found in Iran recently [4].

*C. auris* can infect or colonize in humans, especially the low-immunity patients in the intensive care unit. Infection and colonization of *C. auris* are associated with varied treatment strategies and clinical outcomes, so they should be differentiated. Blood stream infections (BSI) are the most common infections with serious outcomes. Overall mortality of *C. auris* and that for patients with BSI may be as high as 59 and 68% respectively [3]. Nevertheless, other studies reported different data.

Due to its transmissibility, multidrug resistance and severe outcomes, *C. auris* is called “superbug fungus”. Due to the low incidence of *C. auris*, no large-scale epidemiology studies were reported by now. Therefore, a comprehensive study was needed to summarize the global epidemiology of *C. auris*. In this present study, we performed a systematic review and meta-analysis to estimate the case count, drug resistance and mortality of *C. auris*. Moreover, factors that may affect the mortality such as BSI, clade and drug resistant patterns of *C. auris* were also analyzed.

Methods

Search strategies and study selection

This systematic review and meta-analysis was carried out according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We systematically searched Pubmed, Embase and Cochrane databases from inception until October 6, 2019 with the only keyword “Candida auris”. Additional studies were obtained by screening the references of eligible studies. Besides, we also searched the websites of Centers for Disease Control and Prevention (CDC), European Centers for Disease Control and Prevention (ECDC) and Public Health England (PHE). Three objectives of this study were case count, drug resistance and mortality of *C. auris*. Since CDC has established breakpoints for fluconazole, amphotericin B, caspofungin, micafungin and anidulafungin in *C. auris* (fluconazole \(\geq32\), amphotericin B \(\geq2\), anidulafungin \(\geq4\), caspofungin \(\geq2\) and micafungin \(\geq4\) deemed to be drug-resistant), only these drugs were analyzed in this present study.

Inclusion and exclusion criteria

All study formats met the following criteria were included in the meta-analysis: 1) Studies that reported the information of case count, drug resistance and mortality of *C. auris*, with no limit regarding the diagnostic test used for detecting *C. auris*. 2) Studies that provided the case count of patients with *C. auris*, number of resistant isolates/total number of *C. auris* isolates, number of deaths/total number of cases; 3) Studies with sample size larger than 5 for meta-analysis of drug resistance and mortality. While studies met the following criteria were excluded from the analysis: 1) Duplicate studies contained the same patients; 2) For meta-analysis of drug resistance of *C. auris*, studies of which the drug resistance data can’t be reinterpreted according to the CDC breakpoints.

Data extraction

Title and abstract review of all searched articles was completed by two of the authors (Jingjing Chen and Sufei Tian) to identify relevant studies on the clinical report of *C. auris*. Then full texts of relevant articles were independently reviewed by two of the authors (Xiaoxu Han and Sufei Tian) to determine eligible studies by research objectives. Data in the articles were collected with a standardized form by two of the authors (Jingjing Chen and Xiaoxu Han) independently. Disagreements were discussed by three authors to reach consensus. The following information was extracted: first author’s name, publication year, country, research time, study design, clade, case count, sample type, mortality, drug resistance patterns, methods of drug resistance methods. Drug resistant data were reinterpreted according to the CDC breakpoints.

Quality of the studies included for mortality and drug resistance analysis were assessed by the Agency for Healthcare Research and Quality (AHRQ) checklist (https://www.ncbi.nlm.nih.gov/books/NBK35156/). This 11-item checklist assesses studies in terms of the source of information, inclusion and exclusion criteria, selection of participants, researcher bias, quality assurance, possible confounding variables, handling of missing data, participant response rates, and completeness of data collection. An item would be scored “1” for “YES” and scored “0” for “NO” or “UNCLEAR”. Article quality was classified as follows: low quality = 0–3; moderate quality = 4–7; high quality = 8–11.

Statistical analysis

The pooled estimate and corresponding 95% confidence interval (CI) were calculated with STATA11.0 software. Statistical heterogeneity was evaluated with Q statistic \((p < 0.10\) indicating statistically significance) and quantified using the \(I^2\) index. Due to the heterogeneity among
studies, all pooled estimates were performed with random-effects model. Furthermore, we did subgroup analyses for mortality stratified by continents, publication year / research year, clade of *C. auris*, sample type (BSI and non-BSI) and drug resistance rate (higher than overall estimate and lower than overall estimate). Moreover, meta-regression was performed to assess risk factors associated with mortality, with variables such as bloodstream infection, clade, fluconazole resistance, amphotericin B resistance, continent, and publication year included into the analysis. Sensitivity analysis was also performed by omission of studies. Begg’s and Egger’s tests were used to assess publication bias, with $p < 0.05$ deemed as statistically significant.

**Results**

**Search and identification of eligible studies**

As shown in Figure S1, a total of 577 citations were obtained according to the designed search strategy as described in methods. Among them, 97 eligible articles on the clinical report of *C. auris* were selected for further evaluation and 67 studies were included in the meta-analysis. Finally, 57, 21 and 19 studies were enrolled in the analysis for case count, drug resistance and mortality of *C. auris* respectively [1, 4–67].

The publication year of eligible studies ranged from 2009 to 2019. Most studies were observational studies except for two studies which were case-control studies [14, 26]. Detailed characteristics of the eligible articles were summarized in Table S1. The mean quality score of the studies included in the meta-analysis for mortality and drug resistance patterns was 6.2 (range: 4–9), with only one high quality study (Table S2). The main problems of the included articles were lack of information on quality assurance, possible confounding variables, handling of missing data, and completeness of data collection.

**Case count and clade of *C. auris***

A total of 4733 cases of *C. auris* were reported in 33 countries (aligning in descending order: South Africa, United States of America, India, Spain, United Kingdom, South Korea, Colombia, Pakistan, Kenya, Kuwait, China, Russia, Venezuela, Japan, Panama, Israel, Oman, Germany, Brazil, Saudi Arabia, Singapore, France, Australia, Malaysia, Netherlands, Belgium, Norway, Switzerland, United Arab Emirates, Canada, Iran, Greece and Italy) from six continents. The earliest report was in 2009 in Japan, and the earliest isolate of *C. auris* traced back to 1996 in South Korea as showed by several screening experiments [16, 68]. Moreover, an epidemic curve which depicted the case count of *C. auris* by detection year was drawn with studies that contained the detailed information. Notably, this was based on publication data rather than surveillance data. It showed that most cases were detected between 2013 and 2019, peaking in 2016 and decreasing thereafter.

Different clades of *C. auris* were reported to emerge simultaneously from different continents. Four clades of *C. auris* have unique geographical characteristics. Clade I was mainly reported in India, Pakistan, Kuwait, Russia, United States, United Kingdom, Germany, Malaysia, Netherlands, Italy, etc.; And Clade II were mainly in Japan and South Korea. Clade III was mainly found in South Africa, United States, United Kingdom and China, whereas Clade IV mainly distributed in Colombia and Venezuela. Clade I and III were the most prevalent clades which have more reported cases and wider geographical distribution. The case count and clade of *C. auris* stratified by country were shown in Fig. 1.

**Blood stream infection of *C. auris***

Infection and colonization of *C. auris* should be differentiated due to varied clinical significance. However, it is difficult to perform due to unavailable data in the original studies. Therefore, rate of BSI which is the most common and serious infection is analyzed instead. Studies enrolled only the candidaemia patients of *C. auris* were excluded. As shown in Fig. 2a, the frequency of BSI of *C. auris* varied between studies [25, 36, 37], with a pooled rate of blood stream infection of 32% (95% CI: 21–42%). However, heterogeneity ($p = 0.00$, $I^2 = 98.7\%$) was observed between studies. Subgroup analysis showed that Clade I and Clade IV of *C. auris* has a high percentage of BSI compared to Clade II and Clade III (Fig. 2b). It is worth mentioning that Clade II has a low rate of BSI rate with ear discharge as the main specimen type, which is different from the other clades of *C. auris* [9, 17, 69].

**Drug resistance patterns**

Meta-analyses of drug resistance were performed with data obtained according to the breakpoints for *C. auris* established by CDC. As shown in Fig. 3, the pooled resistance rate for fluconazole and amphotericin B were 91% (95% CI: 88–95%) and 12% (95% CI: 7–17%) respectively. Yet there was significant heterogeneity between studies. Besides, publication bias was observed for meta-analysis of resistance rate for fluconazole (Figure S2), yet trim and fill method did not get good result. Meta-analyses for the resistance rate to echinocandins could not be performed as resistance for these drugs are rare in *C. auris*. Descriptive analysis was performed alternatively with frequencies of resistant isolates divided by total isolates. Therefore, resistance rate to caspofungin, micafungin and anidulafungin in *C. auris* were 12.1% ($n/N = 101/838$), 0.8% ($n/N = 8/927$) and 1.1% ($n/N = 9/840$) respectively. However, almost all isolates resistant to caspofungin were from India, with resistance
rate of 23.6% (n/N = 100/424) for Indian isolates and 0.2% (n/N = 1/414) for non-Indian isolates.

Mortality of *C. auris*

The overall crude mortality of *C. auris* ranged from 0 to 78%, with a pooled crude mortality of 39% (95% CI: 32–47%, Fig. 4). While the mortality for BSI of *C. auris* was 45% (95% CI: 39–51%, Figure S3). Negligible publication bias and significant heterogeneity (p < 0.05; $I^2 = 72\%$) was observed. Sensitivity analysis indicated that the pooled estimate was quite stable when excluding any of the studies.

Then subgroup analyses were performed to assess factors that may influence the mortality of *C. auris*, such as continent, publication year, clade of *C. auris*, BSI, and resistance to fluconazole, amphotericin B (Table 1). For the subgroup analysis by clade, as most studies contained patients infected with *C. auris* of Clade I, so we stratified the studies as Clade I and non-Clade I, which showed no significant difference. Studies with *C. auris* of Clade II were not included in this analysis as lack of data which may be due to rare death. Notably, mortality of patients with BSI of *C. auris* (45, 95% CI: 39–51%) was higher than that in non-BSI patients (21, 95% CI: 8–33%). Besides, mortality of *C. auris* in Europe (20, 95% CI: 4–37%) was lower than that in Asia (44, 95% CI: 38–51%). However, we did not find associations between mortality and resistance to fluconazole, amphotericin B, clade or publication year.

**Discussion**

*C. auris* is a globally spreading yeast with more than 4733 cases reported by now, covering at least 33 countries from six continents. It showed 91% resistance to fluconazole, 12% resistance to amphotericin B, 12% resistance to caspofungin and were highly sensitive to micafungin and anidulafungin. The pooled crude mortality of *C. auris* was 39%, while the mortality of BSI was 45%. Subgroup analyses showed that cases of BSI and from Europe were factors that affected the mortality. This study is helpful for the surveillance and clinical management of *C. auris*.

Although a simple meta-analysis of *C. auris* was performed previously [70], we comprehensively described the epidemic situation and mortality of *C. auris*. 

---

Fig. 1 Global reported cases of *C. auris* by country (adapted from Robinson projection map). The reported case count of patients with *C. auris* and clade(s) in different countries were represented in descending order. An epidemic curve showing case count of *C. auris* by year was also portrayed based on publication data.
Referring to the epidemic situation of *C. auris*, over 4733 cases from 33 countries were reported. However, the actual number of cases was underreported in this study. There may be publication bias and bias based on type of surveillance conducted. First of all, there are countries with *C. auris* cases but not published in literature, such as Thailand, Chile and Bangladesh, Austria and Costa Rica [52, 71]. Secondly, there is bias based on type of surveillance conducted, as screening for *C. auris* may not be adequate in some countries. For instance, although many cases were reported in South Africa and Kenya, the other underdeveloped countries in Africa did not report cases of *C. auris*. Moreover, many patients colonized with *C. auris* which are difficult to identify may be overlooked [9]. This indicates that more intensive surveillance is needed to better understand its epidemic situation. An epidemic curve was drawn using studies with detection time, which showed a peak in 2016 and a fall thereafter. Whether this was a true reduction in case count or a delay in case report needs further follow-up.

As for the clade of *C. auris*, Clade I and Clade III are the geographically prevalent clade, whereas Clade II and Clade VI showed local epidemic. Besides, we found that Clade I and Clade VI of *C. auris* exhibits high BSI rate in comparison with the other clades, which was deemed as severe disease with high mortality. Whether this difference was due to specific genetic features deserves further exploration. Furthermore, as there are genes for mating and meiosis in *C. auris*, sexual recombination can occur with frequent travelling of people with *C. auris*. Consequently, the genome of *C. auris* may become more complicated.

In addition, antifungal resistance patterns were also analyzed. Resistance rate of *C. auris* to fluconazole, amphotericin B, caspofungin, micafungin and anidulafungin were 91, 12, 12.1, 0.8 and 1.1% respectively. It was surprising that Indian isolates showed a resistance rate of 23.6% for caspofungin, which deserves the attention of the clinicians but also needs further validation. Like the other species in the Metschnikowiaceae family (such as *C. haemulonii*), antifungal resistance is common in *C. auris*, limiting the treatment options. Acquired resistance through treatment is another concern which deserves clinicians’ attention and further study [5]. Mutations in ERG11 (Y132F, K143R and F126L) and FKS1 (S639F) play an important role in the drug resistance of fluconazole and echinocandins, which should be detected to guide clinical treatment [72]. Drug resistance to amphotericin B may be inducible and transient, nonetheless the
### A

| Study                          | ES (95% CI)            | Weight (%) |
|-------------------------------|------------------------|------------|
| Iguchi, S. 2019              | 0.20 (-0.05-0.45)      | 1.74       |
| Hamprecht, A. 2019           | 0.93 (0.74-1.12)       | 2.61       |
| Ceballos-Garzon, A. 2019     | 0.40 (-0.03-0.83)      | 0.66       |
| Adam, R. D. 2019             | 0.98 (0.91-1.04)       | 7.12       |
| Sayeed, M. A. 2019           | 0.99 (0.97-1.06)       | 8.94       |
| Kwon, Y. J. 2019             | 0.62 (0.50-0.74)       | 4.54       |
| Tian, S. 2018                | 0.97 (0.88-1.06)       | 5.86       |
| Ruiz-Gaitan, A. 2018         | 0.99 (0.95-1.02)       | 8.56       |
| Khan, Z. 2018                | 0.99 (0.97-1.02)       | 8.86       |
| Eyre, D. W. 2018             | 0.99 (0.98-1.01)       | 9.05       |
| Chowdhary, A. 2018           | 0.90 (0.87-0.93)       | 8.66       |
| Chow, N. A. 2018             | 0.89 (0.83-0.95)       | 7.29       |
| Arauz, A. B. 2018            | 0.77 (0.54-1.00)       | 1.98       |
| Ben-Ami, R. 2017             | 0.92 (0.70-1.14)       | 2.09       |
| Rudramurthy, S. M. 2017      | 0.66 (0.55-0.77)       | 5.10       |
| Al-Siyabi, T. 2017           | 0.90 (0.64-1.16)       | 1.58       |
| Schelenz, S. 2016            | 0.99 (0.96-1.02)       | 8.77       |
| Calvo, B. 2016               | 0.97 (0.76-1.05)       | 6.58       |
| Overall (I²=88.7%, p=0.000)  | 0.91 (0.88-0.95)       | 100.00     |

**Random effects model**

### B

| Study                          | ES (95% CI)            | Weight (%) |
|-------------------------------|------------------------|------------|
| Iguchi, S. 2019              | 0.05 (-0.09-0.19)      | 5.67       |
| Ceballos-Garzon, A. 2019     | 0.10 (-0.16-0.36)      | 2.56       |
| Adam, R. D. 2019             | 0.02 (-0.04-0.09)      | 8.51       |
| Sayeed, M. A. 2019           | 0.08 (0.01-0.15)       | 8.45       |
| Kwon, Y. J. 2019             | 0.01 (-0.01-0.03)      | 9.82       |
| Tian, S. 2018                | 0.03 (-0.06-0.12)      | 7.44       |
| Ruiz-Gaitan, A. 2018         | 0.01 (-0.02-0.05)      | 9.58       |
| Khan, Z. 2018                | 0.23 (0.12-0.34)       | 6.62       |
| Eyre, D. W. 2018             | 0.18 (0.09-0.26)       | 7.72       |
| Chowdhary, A. 2018           | 0.08 (0.05-0.11)       | 9.71       |
| Chow, N. A. 2018             | 0.33 (0.24-0.43)       | 7.36       |
| Arauz, A. B. 2018            | 0.08 (-0.07-0.22)      | 5.32       |
| Ben-Ami, R. 2017             | 0.83 (0.54-1.13)       | 2.11       |
| Rudramurthy, S. M. 2017      | 0.14 (0.06-0.21)       | 7.99       |
| Al-Siyabi, T. 2017           | 0.40 (-0.03-0.83)      | 1.14       |
| Overall (I²=87.5%, p=0.000)  | 0.12 (0.07-0.17)       | 100.00     |

**Random effects model**

---

**Fig. 3** Forest plot on the drug resistance of *C. auris* to fluconazole (a) and amphotericin B (b)
Table 1 Subgroup analyses of pooled mortality

| Factors             | Group   | Number of studies | Pooled crude mortality (95%CI) | $I^2$ (%) | $p$ value |
|---------------------|---------|-------------------|--------------------------------|-----------|-----------|
| Bloodstream infection | Yes     | 15                | 0.45 (0.39–0.51)               | 41        | 0.002     |
|                     | No      | 5                 | 0.21 (0.08–0.33)               | 40        | Ref       |
| Clade               | Clade I | 11                | 0.39 (0.31–0.47)               | 49        | 0.343     |
|                     | Non-Clade I | 4   | 0.31 (0.14–0.48)          | 83        | Ref       |
| FLC resistance      | Higher  | 10                | 0.29 (0.21–0.38)               | 60        | 0.415     |
|                     | Lower   | 3                 | 0.49 (0.29–0.70)               | 70        | Ref       |
| AmB resistance      | Higher  | 6                 | 0.29 (0.19–0.40)               | 45        | 0.159     |
|                     | Lower   | 6                 | 0.43 (0.32–0.53)               | 62        | Ref       |
| Continent           | Asia    | 9                 | 0.44 (0.38–0.51)               | 0         | 0.000     |
|                     | America | 5                 | 0.43 (0.27–0.59)               | 78        | 0.164     |
|                     | Africa  | 2                 | 0.37 (0.21–0.53)               | 81        | 0.303     |
|                     | Europe  | 3                 | 0.20 (0.04–0.37)               | 66        | Ref       |
| Publication Year    | 2018–2019 | 11           | 0.42 (0.31–0.53)               | 86        | 0.769     |
|                     | 2016–2017 | 5         | 0.39 (0.30–0.48)               | 0         | 0.415     |
|                     | 2013–2015 | 3         | 0.47 (0.31–0.63)               | 0         | Ref       |

*FLC fluconazole, AmB amphotericin B*
mechanisms are not well understood yet. Moreover, genomic insights and analyses of gene expression showed that genes associated with oligopeptide and ABC transporters, iron transporters, glycosylphosphatidylinositol-anchored proteins, etc may be involved in drug resistance of *C. auris* [73, 74].

The pooled crude mortality of *C. auris* infection was 39%, with an overall mortality of BSI of 45%. Previous meta-analysis indicated that the mortality of candidemia in Europe was 38% [75]. Moreover, the mortality of *C. auris* was also compared with other drug-resistant organisms, which spread in similar ways in healthcare centers. A meta-analysis showed that the mortality of patients infected with multidrug-resistant *Pseudomonas aeruginosa* was 44.6% [76]. Besides, the overall mortality of BSIs of vancomycin resistant *Staphylococcus aureus* and carbapenem-resistant *Klebsiella pneumoniae* were 26.8 and 54.3% respectively [77, 78]. This indicates that the mortality of *C. auris* candidemia was a little higher than the other candidemia and similar to that of some drug-resistant bacterial BSIs.

There was heterogeneity between studies, so we investigated factors that may affect the mortality of *C. auris* infection, such as clade, BSI, drug resistance, continent and publication year. Results showed that the mortality of BSI of *C. auris* was higher than that of non-BSI. Besides, the mortality reported in Europe was lower than that in Asia. This indicated that types of infection and continent were factors for significant heterogeneity. In addition, mortality at any time rather than 30-day mortality, clades of *C. auris*, study designs may be the causes of heterogeneity. Reasons explaining for lower mortality in Europe may be as follows: (1) high percentage of non-BSI [10, 19, 26]; (2) better healthcare systems in developed countries with more intensive surveillance and rational treatment.

Although this study was a comprehensive analysis, some limitations should be noted. Firstly, there was an underestimation in case count of *C. auris* due to publication bias and bias based on type of surveillance conducted. What’s more, most studies included were observational studies, crude mortality rather than attributable mortality was analyzed. Furthermore, significant heterogeneity was observed between studies, well-designed case-control studies should be carried out to estimate the resistance patterns and mortality of *C. auris* accurately.

*C. auris* is an emerging pathogen covering over 33 countries, which may have a decrease in case count after 2016. It showed high resistance to fluconazole, moderate resistance to amphotericin B, and high sensitivity to echinocandins. The crude mortality for BSI of *C. auris* was 45% which was similar to some drug-resistant bacteria previously reported.

In summary, *C. auris* displayed similar characteristics to some drug resistance organisms. *C. auris* may not be so scary, yet it should not be underestimated, intensive prevention and control should be taken.

**Supplementary Information**
The online version contains supplementary material available at https://doi.org/10.1186/s12879-020-05543-0.

**Additional file 1: Table S1** Characteristics of included studies.  
**Additional file 2: Table S2** Quality assessment of the studies included in the meta-analysis for mortality and drug resistance patterns.  
**Additional file 3: Figure S1** Flowchart showing study search and selection.  
**Additional file 4: Figure S2** Funnel plot for BSI rate of *C. auris* (A), drug resistance of *C. auris* to fluconazole (B) and amphotericin B (C), crude mortality (D).  
**Additional file 5: Figure S3** Forest plot on the crude mortality for BSI of *C. auris*.

**Abbreviations**  
BSI: Bloodstream infections; CDC: Centers for Disease Control and Prevention; ECDC: European Centers for Disease Control and Prevention; PHE: Public Health England; AHRQ: Agency for Healthcare Research and Quality; CI: Confidence interval

**Acknowledgments**
We appreciate Katie Forsberg from the CDC for providing additional information on the case count of *C. auris*.

**Authors’ contributions**
SH, HX and CJ conceived and designed the study. CJ and TS performed title and abstract review of studies, HX and TS reviewed relevant articles for eligibility. Data were collected and analyzed by CJ, WQ, ZB and HX. CJ, TS, CY and HX wrote the manuscript. All authors read and approved the final manuscript.

**Funding**
This work was supported by Laboratory medicine innovation unit, Chinese Academy of Medical Sciences (2019RU017) and National Key Specialist Construction Project for Clinical Laboratory Medicine.

**Availability of data and materials**
The datasets used and/or analyzed of the current study are available from the corresponding author on request.

**Ethics approval and consent to participate**
Not Applicable.

**Consent for publication**
Not Applicable.

**Competing interests**
The authors declare that they have no conflicts of interest.

**Author details**
1. Department of Laboratory Medicine, the First Affiliated Hospital of China Medical University, No. 155, Nanjing North Street, Heping District, Shenyang 110001, China.  
2. National Clinical Research Center for Laboratory Medicine, the First Affiliated Hospital of China Medical University, Shenyang 110001, China.  
3. Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, 79 Qingchun Street, Hangzhou 310003, China.  
4. Department of Clinical Epidemiology and Center of Evidence-Based Medicine, the First Hospital of China Medical University, Shenyang 110001, China.

Received: 10 October 2019 Accepted: 26 October 2020
Published online: 11 November 2020

**References**
1. Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. *Candida auris* sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009;53(1):41–4.
2. Rhodes J, Fisher MC. Global epidemiology of emerging Candida auris. Curr Opin Microbiol. 2019;52:84–9.
3. Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhry A, Govender NP, et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis. 2017;65(4):519–40.
4. Chow NA, Gade L, Tsay SV, Forsberg K, Greenko JA, Southwick KL, et al. Multiple introductions and subsequent transmission of multidrug-resistant Candida auris in the USA: a molecular epidemiological survey. Lancet Infect Dis. 2018;18(12):1377–84.
5. Biagi MJ, Wiederhold NP, Gibas C, Wickes BL, Lozano V, Bealeid SC, et al. Development of High-Level Echinocandin Resistance in a Patient With Recurrent Candida auris Candidemia Secondary to Chronic Candida. Open Forum Infect Dis. 2019;6(7):ofz626.
6. van Schalkwyk E, Mperms RS, Thomas J, Shuping L, Ismail H, Lowman W, et al. Epidemiologic shift in Candidemia driven by Candida auris, South Africa, 2016-2017(1). Emerg Infect Dis. 2019;25(9):1698–707.
7. Chibabhai V, Fadana V, Bosman N, Nana T. Comparative sensitivity of 1,3-beta-D-glucan for common causes of candidaemia in South Africa. Mycoses. 2019;62(11):1023–8.
8. Sana F, Hussain W, Zaman G, Satti L, Khusnud U, Khadm MT. Candida auris associated outbreak report from Pakistan: a success story of infection control in ICU of a tertiary care hospital. J Infect Hosp. 2019;10(3):108–10.
9. Iguchi S, Itakura Y, Yoshida A, Kamada K, Mizushima R, Arai Y, et al. Candida auris: a pathogen difficult to identify, treat, and eradicate and its characteristics in Japanese strains. J Infect Chemother. 2019;25(10):743–9.
10. Hamprecht A, Barber AE, Mellinghoff SC, Thelen P, Walther G, Yu Y, et al. Candida auris in Germany and Previous Exposure to Foreign Healthcare. Emerg Infect Dis. 2019;25(9):1763–5.
11. Ceballos-Garzon A, Cortes G, Morio F, Zamora-Cruz EL, Linares MY, Ariza BE, et al. Comparison between MALDI-TOF MS and MicroScan in the identification of emerging and multidrug resistant yeasts in a four-level hospital in Bogota, Colombia. BMC Microbiol. 2019;19(1):106.
12. Adam RD, Revathi G, Okinda N, Fontaine M, Shah J, Kagotho E, et al. Multidrug-Resistant Candida haemulonii and C. auris, Tel Aviv, Israel. Emerg Infect Dis. 2017;23(1):195–203.
13. Schelenz S, Hagen F, Rhodes JL, Abdolrasouli A, Chowdhary A, et al. Comparison between MALDI-TOF MS and MicroScan in the identification of emerging and multidrug resistant yeasts in a four-level hospital in Bogota, Colombia. BMC Microbiol. 2019;19(1):106.
14. Proress A, Revathi G, Okinda N, Fontaine M, Shah J, Kagotho E, et al. Multidrug-Resistant Candida auris in Kenya and Tanzania: a comparative study. J Infect Chemother. 2017;23(1):195–203.
15. Adams E, Quinn M, Tsay S, Poirier E, Chaturvedi S, Southwick K, et al. Candida auris candidaemia in Indian ICUs: analysis of risk factors. J Antimicrob Chemother. 2017;72(6):1794–801.
16. Morales-Lopez SE, Parra-Giraldo CM, Ceballos-Garzon A, Martinez HP, Rodriguez GJ, Alvarez-Moreno CA, et al. Invasive infections with multidrug-resistant yeast Candida auris, Colombia. Emerg Infect Dis. 2017;23(1):162–4.
17. Al-Siyabi T, Al Busaidi I, Balkhi R, Al-Muhammadi Z, Al-Salti M, Al-Adawi B. First report of Candida auris in Oman: clinical and microbiological description of five candidaemia cases. J Infect. 2017;75(4):373–6.
18. Schelenz S, Hagen F, Rhodes JL, Abdulrasouli A, Chowdhry A, Hall A, et al. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control. 2016;5:35.
19. Prakash A, Sharma C, Singh A, Kumar Singh P, Kumar A, Hagen F, et al. Evidence of genotypic diversity among Candida auris isolates by multilocus sequence typing, matrix-assisted laser desorption ionization time-of-flight mass spectrometry and amplified fragment length polymorphism. Clin Microbiol Infect. 2016;22(3):277 e1–9.
20. Calvo B, Melo AS, Perozo-Mena A, Hernandez M, Francisco EC, Hagen F, et al. First report of Candida auris in America: clinical and microbiological aspects of 18 episodes of candidemia. J Infect. 2016;73(6):369–74.
21. Chowdhry A, Ahir Kumar V, Sharma C, Prakash A, Agawan K, Babu R, et al. Multidrug-resistant endemic clonal strain of Candida auris in India. Eur J Clin Microbiol Infect Dis. 2014;33(6):619–26.
22. Samra S, Kumar N, Sharma S, Goyal D, All T, Mehta Y, et al. Candidemia caused by amphotericin B and fluconazole resistant Candida auris. Indian J Med Microbiol. 2013;31(1):90–1.
23. Chowdhry A, Sharma C, Duggal S, Agawan K, Prakash A, Singh PK, et al. New clonal strain of Candida auris, Delhi, India. Emerg Infect Dis. 2013;19(10):1670–3.
24. Ding CH, Situ SF, Steven A, Razak MFA. The pitfall of utilizing a commercial biochemical yeast identification kit to detect Candida auris. Ann Clin Lab Sci. 2019;49(4):546–9.
25. Crea F, Codda G, Orsi A, Battaglini A, Giacobbe DR, Delfino E, et al. Isolation of Candida auris from invasive and non-invasive samples of a patient suffering from vascular disease, Italy, July 2019. Euro surveillance. 2019;24(37):1900549.
26. Vogelhank EH, Weersink AL, van Mansfeld R, Chow NA, Meis JF, van Dijk K. The First Two Cases of Candida auris in The Netherlands. J Fungi (Basel, Switzerland). 2019;5(4):91.
44. Supreeth S, Al Ghafri KA, Kumar JR, Al Balushi ZY. First report of Candida auris spondylodiscitis in Oman - A rare presentation. World Neurosurg. 2019;135:335–8.

45. Stathu A, Loukou I, Kikou H, Petrochelou A, Moustaki M, Velegraki A, et al. Isolation of Candida auris from cystic fibrosis patient, Greece, April 2019. Euro Surveillance. 2019;24(29):1900400.

46. Elsayy A, Alqathari A, Alkhuthani N, Marwan D, Abbas A. The second confirmed case of Candida auris from Saudi Arabia. J Infect Public Health. 2019;12(6):907–8.

47. Tang HJ, Lai CC, Lai FJ, Li SY, Liang HY, Hsueh PR. Emergence of multidrug-resistant Candida auris in Taiwan. Int J Antimicrobial Agents. 2019;53(5):505–6.

48. O’Connor C, Bicanic T, Dave J, Evans TJ, Moxey P, Adamu U, et al. Candida auris outbreak on a ward. The unexpected arrival of an anticipated pathogen. J Hosp Infect. 2019;103(1):106–8.

49. Abastabar M, Haghani I, Ahangarkani F, Rezaiz MH, Taghizadeh Armaki M, Rooodgari S, et al. Candida auris otomastoiditis in Iran and review of recent literature. Mycoses. 2019;62(2):101–5.

50. Heath CH, Dyer JR, Pang S, Coombs GW, Gardam DJ. Candida auris sternal osteomyelitis in a man from Kenya visiting Australia, 2015. Emerg Infect Dis. 2019;25(4):192–2.

51. Wang X, Bing J, Zheng Q, Zhang F, Liu J, Yue H, et al. The first isolate of Candida auris vulvovaginitis. J Infect Dev Ctries. 2015;9(4):435.

52. Tan YE, Tan AL. Arrival of Candida auris fungus in Singapore: report of the first 3 cases. Ann Acad Med Singap. 2018;47(7):260–2.

53. Riat A, Neofytos D, Coste A, Harbarth S, Bizzini A, Grandbastien B, et al. First report of sporadic cases of Candida auris in Colombia. Int J Infect Dis. 2018;69:63.

54. Mohamed Tap R, Lim TC, Kamardin NA, Gisapu SJ, Abd Razak MF, Ahmad N, et al. A fatal case of Candida auris and Candida tropicalis Candidemia in Neutropenic patient. Mycopathologia. 2018;183(3):559–64.

55. Chen Y, Zhao J, Han L, Qi L, Fan W, Liu J, et al. Emergency of fungemia cases caused by fluconazole-resistant Candida auris in Beijing, China. J Infect. 2018;77(6):561–71.

56. Belkin A, Gazit Z, Keller N, Ben-Ami R, Wieder-Finesod A, Novikov A, et al. Candida auris infection leading to nosocomial transmission, Israel, 2017. Emerg Infect Dis. 2018;24(4):801–4.

57. Alatoom A, Sartawi M, Laviol K, Abdel-Wareth L, Thomsen J, Nusair A, et al. Persistent candidemia despite appropriate fungal therapy first case of Candida auris from the United Arab Emirates. Int J Infect Dis. 2018;70:36–7.

58. Abdalhamid B, Almahgabi R, Alhawadi S, Ommani A. First report of Candida auris infections from Saudi Arabia. J Infect Public Health. 2018;11(4):598–9.

59. Schwartz IS, Hammond GW. First reported case of multidrug-resistant Candida auris in Canada. Can Commun Dis Rep. 2018;43(7–8):150–3.

60. Mohsin J, Hagen F, Al-Balushi ZAM, de Hoog GS, Chow NA, Berkow EL, et al. Genomic insights into multidrug-resistance, mating and virulence in Candida auris and related emerging species. Nat Commun. 2018;9(1):5346.

61. Koehler P, Stecher M, Cornely OA, Koehler D, Vehreschild M, Bohlius J, et al. Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis. Clin Microbiol Infect. 2019;25(10):1200–12.

62. Matos ECO, Andriolo RB, Rodrigues YC, Lima PDL, Carneiro LM, Kiy X. Mortality in patients with multidrug-resistant Pseudomonas aeruginosa infections: a meta-analysis. Rev Soc Bras Med Trop. 2018;51(4):415–20.

63. Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob. 2017;16(1):18.

64. Rabani O, Glickman ME, Girgis R, Tramontana EA, Zaidi AK, Majeed A, et al. Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections: a systematic review and meta-analysis. Jama. 2014;312(15):1552–64.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions